Author:
Chiu Yi-Ting,Deutch Ariel Y.,Wang Wei,Schmitz Gavin P,Huang Karen Lu,Kocak D. Dewran,Llorach Pierre,Bowyer Kasey,Liu Bei,Sciaky Noah,Hua Kunjie,Chen Chongguang,Mott Sarah E.,Niehaus Jesse,DiBerto Jeffrey F.,English Justin,Walsh Jessica J.,Scherrer Grégory,Herman Melissa A,Wu Zhuhao,Wetsel William C,Roth Bryan L
Abstract
ABSTRACTPsychedelic drugs like lysergic acid diethylamide (LSD) and psilocybin have emerged as potentially transformative therapeutics for many neuropsychiatric diseases, including depression, anxiety, post-traumatic stress disorder, migraine, and cluster headaches. LSD and psilocybin exert their psychedelic effects via activation of the 5-hydroxytryptamine 2A receptor (HTR2A). Here we provide a suite of engineered mice useful for clarifying the role of HTR2A and HTR2A-expressing neurons in psychedelic drug actions. We first generatedHtr2a-EGFP-CT-IRES-CreERT2 mice (CT:C-terminus) to independently identify both HTR2A-EGFP-CT receptors and HTR2A-containing cells thereby providing a detailed anatomical map of HTR2A and identifying cell types that express HTR2A. We also generated a humanizedHtr2amouse line and an additional constitutiveHtr2A-Cre mouse line. Psychedelics induced a variety of known behavioral changes in our mice validating their utility for behavioral studies. Finally, electrophysiology studies revealed that extracellular 5-HT elicited a HTR2A-mediated robust increase in firing of genetically-identified pyramidal neurons--consistent with a plasma membrane localization and mode of action. These mouse lines represent invaluable tools for elucidating the molecular, cellular, pharmacological, physiological, behavioral, and other actions of psychedelic drugsin vivo.
Publisher
Cold Spring Harbor Laboratory